http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11090334-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_313ed105a5d782d26b3187a3d5b1dddf |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2878 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70521 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-725 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate | 2017-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e5acee4e722db15c2e9701575acc25c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09a57ff270a17ec56d0cf27b6e09d940 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78702bda1e0b33326e8b8bb4dff2dd00 |
| publicationDate | 2021-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-11090334-B2 |
| titleOfInvention | Chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof |
| abstract | A chimeric antigen receptors (CARs) specific to B-cell maturation antigen (BCMA), a recombinant expression vector and a method for the development of the genetically modified immune effector cells especially natural killer-92 cells (NK-92 cells) that target Multiple Myeloma (MM) and other hematological malignancies. The invention encompasses a single chain variable region (scFv) from BCMA specific antibody fused via transmembrane domain to intracellular signaling domain and two co-stimulatory molecules. Expression of CARs across the plasma membrane of immune effector cells such as natural killer cells (NK cells), NK-92 cells, T lymphocytes (T cells) and natural killer T cells (NKT cells) with exposed scFv interacting with the BCMA tumor target. The interaction initiates cascade of events through the intracellular stimulatory and signaling domains leading to the activation of immune effector cells followed by lysis of the tumor. The invention also includes methods of administering a genetically modified immune effector cells expressing a CAR that comprises a BCMA binding domain. FIG. 4 is the representative figure. |
| priorityDate | 2016-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 448.